{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:07:44Z","timestamp":1790784464995,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pcd.2022.07.002","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T01:01:04Z","timestamp":1658192464000},"page":"670-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin"],"prefix":"10.1016","volume":"16","author":[{"given":"L\u00e9na","family":"Boullenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Quindroit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Balcaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Calafiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Rochoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Beuscart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Chazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2022.07.002_bib1","unstructured":"International Diabetes Federation, IDF Diabetes Atlas 2017, (2017). \u3008https:\/\/diabetesatlas.org\/\u3009 (accessed March 2, 2021)."},{"key":"10.1016\/j.pcd.2022.07.002_bib2","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2337\/dci19-0017","article-title":"Understanding the economic costs of diabetes and prediabetes and what we may learn about reducing the health and economic burden of these conditions","volume":"42","author":"O\u2019Connell","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2022.07.002_bib3","unstructured":"Haute Autorit\u00e9 de Sant\u00e9, Strat\u00e9gie m\u00e9dicamenteuse du contr\u00f4le glyc\u00e9mique du diab\u00e8te de type 2, Haute Autorit\u00e9 de Sant\u00e9. (2013). \u3008https:\/\/www.has-sante.fr\/jcms\/c_1022476\/fr\/strategie-medicamenteuse-du-controle-glycemique-du-diabete-de-type-2\u3009 (Accessed March 2, 2021)."},{"key":"10.1016\/j.pcd.2022.07.002_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000435","article-title":"Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study","volume":"5","author":"Gottlieb","year":"2017","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.pcd.2022.07.002_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term Trends in Antidiabetes Drug Usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes","volume":"41","author":"Montvida","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2022.07.002_bib6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2169\/internalmedicine.9481-17","article-title":"Changes in antidiabetic drug prescription and glycemic control trends in elderly patients with type 2 diabetes mellitus from 2005-2013: an analysis of the national center diabetes database (NCDD-03)","volume":"57","author":"Yamamoto-Honda","year":"2018","journal-title":"Intern Med."},{"key":"10.1016\/j.pcd.2022.07.002_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the European Association for the study of diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2022.07.002_bib8","unstructured":"M. Virally, M. Laloi-Michelin, M. Coupaye, J. Kevorkian, P. Guillausseau, Diab\u00e8te de type 2 et insulinoth\u00e9rapie: situations transitoires et d\u00e9finitives, Undefined. (2005). \/paper\/Diab%C3%A8te-de-type-2-et-insulinoth%C3%A9rapie-%3A-situations-Virally-Laloi-Michelin\/3bb9f2577544a9a47828d0bf0abeb8c6bdc0e2aa (Accessed April 14, 2021)."},{"key":"10.1016\/j.pcd.2022.07.002_bib9","unstructured":"Netgen, Place de la metformine dans le traitement du diab\u00e8te de type 2 en 2008, Revue M\u00e9dicale Suisse. (n.d.). \u3008https:\/\/www.revmed.ch\/RMS\/2008\/RMS-160\/Place-de-la-metformine-dans-le-traitement-du-diabete-de-type-2-en-2008\u3009 (Accessed April 14, 2021)."},{"key":"10.1016\/j.pcd.2022.07.002_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9401606","article-title":"Comparison of exenatide and metformin monotherapy in overweight\/obese patients with newly diagnosed type 2 diabetes","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J. Endocrinol."},{"key":"10.1016\/j.pcd.2022.07.002_bib11","first-page":"423","article-title":"Au Nom Des investigateurs M\u00e9decins G\u00e9n\u00e9ralistes, Effects of glimepiride (Amarylle) in type 2 diabetic patients: results of the Belgian study RECORD in general medicine","volume":"61","author":"Radermecker","year":"2006","journal-title":"Rev. Med Liege"},{"key":"10.1016\/j.pcd.2022.07.002_bib12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4103\/ijem.IJEM_176_17","article-title":"Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: indian multicentric randomized trial - START Study","volume":"21","author":"Devarajan","year":"2017","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.pcd.2022.07.002_bib13","first-page":"1044","article-title":"Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus","volume":"32","author":"Campbell","year":"1998","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.pcd.2022.07.002_bib14","unstructured":"A.J. Scheen, L.F.V. Gaal, le m\u00e9dicament du mois Ex\u00e9natide (BYETTA\u00ae) Incr\u00e9tinomim\u00e9tique indiqu\u00e9 dans le traitement du diab\u00e8te de type 2 apr\u00e8s \u00e9chec et en compl\u00e9ment des antidiab\u00e9tiques oraux, Rev Med Liege. (n.d.) 8."},{"key":"10.1016\/j.pcd.2022.07.002_bib15","article-title":"Amelioration du controle glycemique et perte de poids sous exenatide chez des patients diabetiques de type 2: resultats d\u2019une etude retrospective observationnelle multicentrique belge","volume":"64","author":"De Block","year":"2009","journal-title":"Rev. M\u00e9dicale De. Li\u00e8ge."},{"key":"10.1016\/j.pcd.2022.07.002_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/00325481.2017.1387473","article-title":"Albiglutide efficacy and safety in the Latino\/Hispanic subpopulation for the integrated phase III program","volume":"129","author":"Davidson","year":"2017","journal-title":"Post. Med."},{"key":"10.1016\/j.pcd.2022.07.002_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/pds.3586","article-title":"The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis","volume":"23","author":"Liu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.pcd.2022.07.002_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005892","article-title":"A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24\u2005163 patients","volume":"5","author":"Esposito","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.pcd.2022.07.002_bib19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2022.07.002_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.14740\/jocmr2540w","article-title":"Factor analysis of changes in hemoglobin A1c after 12 months of sitagliptin therapy in patients with type 2 diabetes","volume":"8","author":"Yuasa","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.pcd.2022.07.002_bib21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.diabres.2015.05.025","article-title":"The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: a systematic review and meta-analysis","volume":"109","author":"Mishriky","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.pcd.2022.07.002_bib22","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.25011\/cim.v39i2.26481","article-title":"Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis","author":"Foroutan","year":"2016","journal-title":"Clin. Invest. Medicine"},{"key":"10.1016\/j.pcd.2022.07.002_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2022.07.002_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/ijcp.12252","article-title":"Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)","volume":"67","author":"Mathieu","year":"2013","journal-title":"Int J. Clin. Pr."},{"key":"10.1016\/j.pcd.2022.07.002_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13300-014-0064-0","article-title":"Use of vildagliptin in management of type 2 diabetes: effectiveness, treatment persistence and safety from the 2-year real-life VILDA study","volume":"5","author":"Simon","year":"2014","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.pcd.2022.07.002_bib26","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jdiacomp.2016.06.009","article-title":"Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records","volume":"30","author":"Kakara","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.pcd.2022.07.002_bib27","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pcd.2022.07.002_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1753-0407.2012.00223.x","article-title":"Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes","volume":"5","author":"Dobs","year":"2013","journal-title":"J. Diabetes"},{"key":"10.1016\/j.pcd.2022.07.002_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Sitagliptin Study 035 Group, efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2022.07.002_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2981","article-title":"When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy","volume":"34","author":"Avogaro","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.pcd.2022.07.002_bib31","unstructured":"S. Coudreau, Traitements antidiab\u00e9tiques et prise de poids, (2009) 6."},{"issue":"Suppl 2","key":"10.1016\/j.pcd.2022.07.002_bib32","first-page":"55","article-title":"The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor\u2019s office","volume":"119","author":"Fehmann","year":"2001","journal-title":"Fortschr. Der Medizin. Orig."},{"key":"10.1016\/j.pcd.2022.07.002_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3346\/jkms.2014.29.1.90","article-title":"Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study","volume":"29","author":"Lee","year":"2014","journal-title":"J. Korean Med Sci."},{"key":"10.1016\/j.pcd.2022.07.002_bib34","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2337\/diacare.23.7.979","article-title":"Repaglinide\/troglitazone combination therapy: improved glycemic control in type 2 diabetes","volume":"23","author":"Raskin","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2022.07.002_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1507\/endocrj.EJ17-0372","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis","volume":"65","author":"Li","year":"2018","journal-title":"Endocr. J."},{"key":"10.1016\/j.pcd.2022.07.002_bib36","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.clinthera.2017.10.003","article-title":"Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, controlled trial in patients with type 2 diabetes mellitus","volume":"39","author":"Yale","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pcd.2022.07.002_bib37","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/dom.13221","article-title":"Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials","volume":"20","author":"Monami","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2022.07.002_bib38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1055\/s-2007-1003367","article-title":"The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study","volume":"24","author":"Kudlacek","year":"1992","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.pcd.2022.07.002_bib39","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/S1262-3636(14)72241-4","article-title":"O67 \u00c9volution \u00e0 4 ans des traitements insuliniques, de l\u2019HbA1c, des hypoglyc\u00e9mies et du poids chez des patients diab\u00e9tiques de type 2 (DT2) apr\u00e8s mise sous insuline \u2013 \u00c9tude CREDIT","volume":"40","author":"Balkau","year":"2014","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.pcd.2022.07.002_bib40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.diabres.2013.12.038","article-title":"Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data","volume":"103","author":"McAdam-Marx","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.pcd.2022.07.002_bib41","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.pcd.2022.07.002_bib42","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9, Code CIP 2019., (n.d.). \u3008https:\/\/solidarites-sante.gouv.fr\/soins-et-maladies\/medicaments\/glossaire\/article\/code-cip\u3009."},{"key":"10.1016\/j.pcd.2022.07.002_bib43","unstructured":"R Development Core TeamR: a language and environment for statistical computing, (2011). \u3008https:\/\/www.gbif.org\/tool\/81287\/r-a-language-and-environment-for-statistical-computing\u3009 (Accessed April 14, 2021)."},{"key":"10.1016\/j.pcd.2022.07.002_bib44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust Locally Weighted Regression and Smoothing Scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.pcd.2022.07.002_bib45","unstructured":"Haute Autorit\u00e9 de Sant\u00e9, Algorythme antidiab\u00e9tiques., 2013. \u3008https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2013\u201302\/12e_memo_algo-diabete_a3_080213.pdf\u3009."},{"key":"10.1016\/j.pcd.2022.07.002_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1957-2557(17)30139-6","article-title":"Prise de position de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) sur la prise en charge m\u00e9dicamenteuse de l\u2019hyperglyc\u00e9mie du patient diab\u00e9tique de type 2","volume":"11","author":"Darmon","year":"2017","journal-title":"M\u00e9decine Des. Mal. M\u00e9taboliques"},{"key":"10.1016\/j.pcd.2022.07.002_bib47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc16-0985","article-title":"Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013","volume":"40","author":"Lipska","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2022.07.002_bib48","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1210\/jc.2011-1074","article-title":"Weight beneficial treatments for type 2 diabetes","volume":"96","author":"Meneghini","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pcd.2022.07.002_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pcd.2022.07.002_bib50","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2022.07.002_bib51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND Investigators, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2022.07.002_bib52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/osp4.116","article-title":"Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence","volume":"3","author":"Carls","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.pcd.2022.07.002_bib53","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s13300-017-0288-x","article-title":"The real-life effectiveness and care patterns of diabetes management study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): a multicenter, observational, cross-sectional study","volume":"8","author":"Majanovic","year":"2017","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.pcd.2022.07.002_bib54","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.9134","article-title":"Possible sources of bias in primary care electronic health record data use and reuse","volume":"20","author":"Verheij","year":"2018","journal-title":"J. Med. Internet Res."}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991822001267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991822001267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:01:21Z","timestamp":1761696081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991822001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1751991822001267"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2022.07.002","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2022.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.","name":"copyright","label":"Copyright"}]}}